How Do Doctors Decide the Right Cancer Treatment?

Cancer treatment decisions rest on four factors: cancer type, stage, tumour biology from biopsy, and patient fitness. No two patients with the same cancer name get the same plan because these variables differ in every case. A tumour board of oncologists, surgeons, and pathologists reviews each case before treatment begins. Stage and molecular subtype together decide whether treatment intent is curative or palliative.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore, “Treatment decisions in oncology are not made on diagnosis alone. Stage, molecular subtype, patient fitness, and treatment intent all determine what goes into the plan and in what sequence.”

Each variable feeds into a decision that is specific to the patient, not just the cancer type.

• Cancer Stage: Stage determines the baseline treatment pathway. Stage I colon cancer needs surgery alone. Stage III needs surgery plus adjuvant chemotherapy. Same organ, completely different plan.
• Tumour Biopsy: Pathology confirms cancer type, grade, and receptor status. A breast lump is not treated until biopsy confirms whether it is hormone receptor positive, HER2 positive, or triple negative. Each subtype needs a different drug class entirely.
• Molecular Profiling: Genetic testing identifies actionable mutations like EGFR in lung cancer or BRCA in breast cancer. Without this, targeted drugs get prescribed to patients whose tumours will not respond to them.
• Patient Fitness: Age, organ function, and comorbidities decide whether full dose treatment is safe. A fit 45 year old and a 72 year old with cardiac disease cannot receive the same chemotherapy at the same doses.

For more on how Precision Oncology uses molecular data to refine treatment decisions, the service page covers what that process looks like in practice.

Beyond clinical data, several factors push the final plan in one direction or another.

• Treatment Intent: Curative intent targets complete remission. Palliative intent focuses on disease control and quality of life. These two goals produce completely different plans even for the same diagnosis.
• Tumour Board Review: No single specialist sees the whole picture. Decisions made without tumour board review are statistically more likely to be incomplete or revised later.
• Treatment Sequence: Some cancers respond better to chemotherapy before surgery to shrink the tumour first. Pathological response to neoadjuvant treatment is one of the strongest predictors of long term survival in breast and rectal cancers.
• Personalised Matching: Personalized Medicine matches drug selection to individual tumour genetics, not cancer type alone. Two Stage III lung cancer patients may get different drugs because one carries an EGFR mutation and the other does not.

For more on how staging feeds directly into these decisions, our previous blog on 4 Stages Explained covers what each stage means for treatment planning and sequence.

Dr. Sandeep Nayak’s team at MACS Clinic runs every new case through a formal tumour board review combining surgical, medical, and radiation oncology input before committing to a plan. Molecular profiling, staging workup, and fitness assessment are completed before the first treatment decision is made, not after.

Patient here does not get a plan based on the cancer name alone. They get a plan built on their specific stage, subtype, fitness, and treatment intent because those four variables decide whether treatment works or misses.

Call +91 8035740000 to book your consultation.

References

1. Cancer treatment decision making — National Cancer Institute
2. Multidisciplinary cancer care — World Health Organization